HCA Healthcare Balances Growth With Exchange Headwinds

Hca Healthcare ((HCA)) has held its Q2 earnings call. Read on for the main highlights of the call.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

HCA Healthcare’s latest earnings call painted a cautiously balanced picture, as solid underlying profitability and steady demand met a sharp policy-driven shock from health insurance exchange attrition. Management emphasized resilient EPS growth and disciplined cost control, but also underscored a sizable EBITDA drag from a worsening payer mix and lower elective surgeries, tempering investor enthusiasm.

Earnings Per Share Growth

Diluted EPS rose 11% in the quarter and 11% year-to-date, underscoring durable profitability despite mounting headwinds from payer-mix shifts and policy changes. This performance signals that core operations remain healthy, even as management recalibrates expectations to reflect a more challenging reimbursement backdrop.

Volume and Demand Strength Outside Exchanges

Same-facility admissions grew 2.5% and equivalent admissions 2.7% in the second quarter, with insured volumes excluding exchanges up 3.2%. Emergency room visits climbed 3.6%, and emergency inpatient surgeries, which make up around two-thirds of inpatient cases, increased about 2%, highlighting resilient demand for acute care.

Medicaid Supplemental Payment Benefit

HCA recognized $400 million of incremental net benefit from Medicaid supplemental programs in the quarter, including a sizeable $540 million benefit tied to a new Florida program spanning late 2024 to mid-2026. For the full year, management assumes a $300 million to $500 million net benefit, making these payments an important offset to exchange-related pressures.

Capital Investment and Shareholder Returns

The company approved more than $7 billion in capital spending over the next three years to expand capacity and build out outpatient sites, while reaffirming a 2026 CapEx range of $5 billion to $5.5 billion. In the second quarter alone, HCA invested $1.2 billion in CapEx, repurchased $2.1 billion of stock, and paid $171 million in dividends, signaling confidence in its long-term trajectory.

Resiliency Program and Cost Discipline

Financial resiliency initiatives are beginning to show through in the numbers, with same-facility cost per equivalent admission essentially flat year-over-year after adjusting for Medicaid supplemental payments. Sequentially, this metric improved 1.4%, and management expects further savings from digital tools, shared services, and workforce optimization, aiming to protect margins as revenue pressures build.

Network Growth and Outpatient Expansion

HCA expanded its footprint by about 5% year-over-year in the quarter, adding roughly 250 new sites of care and maintaining a pipeline of another 250 to 300 outpatient facilities. Inpatient capacity has also grown over time, from around 37,000 to 42,000 beds, with occupancy rising from roughly 71% to 75%, supporting both scale advantages and patient access.

Revised Full-Year Financial Guidance

For 2026, the company now projects revenue between $77.0 billion and $79.5 billion, adjusted EBITDA of $15.4 billion to $16.1 billion, net income of $6.3 billion to $6.7 billion, and diluted EPS of $28.70 to $30.50. Management framed this updated outlook as a realignment with its long-term 4% to 6% adjusted EBITDA growth target, reflecting a more measured growth runway after incorporating exchange and supplemental payment dynamics.

Health Insurance Exchange Attrition and Payer-Mix Shift

Exchange-covered admissions declined about 15% across the first two quarters, and executives now see nearly a one-for-one shift of these patients into the uninsured category, versus earlier expectations of 80% to 85%. Exchanges currently represent around 6.8% of equivalent admissions, while uninsured admissions have climbed roughly 15% and now account for just over 10% of total equivalent volumes.

Material EBITDA Impact from Exchanges

The unfavorable payer-mix shift linked to exchange attrition reduced adjusted EBITDA by roughly $400 million in the second quarter alone, highlighting the financial weight of this trend. For the full year, management expects exchange-related headwinds of approximately $1.0 billion to $1.2 billion to adjusted EBITDA, a material drag that tempers otherwise healthy operations.

Surgery Volume Declines, Especially Elective Procedures

Surgical volumes softened, with inpatient surgeries down 2.3% and outpatient surgeries down 3.4% in the quarter, pointing to pressure in higher-margin services. Elective inpatient surgeries are down about 6% year-to-date, versus a roughly 2% decline last year, and elective outpatient cases are also under strain, with management citing exchange disenrollment and affordability concerns as key contributors.

Cash Flow and Timing Headwinds

Cash flow from operations fell to $2.3 billion in the quarter, a 45% drop from the prior year, driven largely by timing of Florida Medicaid supplemental payment receipts and last year’s deferral of federal tax payments. Management also flagged a $100 million to $300 million headwind in the second half tied to supplemental payment timing, emphasizing that these are largely timing-related rather than structural cash flow issues.

Guidance Moderation and Concentrated Market Impacts

The updated 2026 outlook reflects roughly a $500 million reduction compared with earlier expectations once exchange assumptions and supplemental payment changes are included, bringing projected adjusted EBITDA growth back to the 4% to 6% range. The exchange impact is not evenly spread, with three divisions in the Gulf Coast, North Florida, and South Atlantic regions accounting for about half of the hit, while elevated professional fees, particularly in anesthesia and radiology, add another layer of cost pressure.

Forward-Looking Guidance and Outlook

Management’s guidance assumes a significant exchange-related EBITDA drag of $1.0 billion to $1.2 billion, partially offset by a $300 million to $500 million net benefit from Medicaid supplemental payments and continued cost savings. Executives expect stronger EBITDA growth in the fourth quarter than in the third, plan to maintain CapEx in the $5.0 billion to $5.5 billion range, and intend to complete most authorized buybacks, signaling confidence that operational levers can offset policy-driven shocks over time.

HCA’s earnings call ultimately balanced resilience with realism, as steady EPS growth, strong non-exchange volumes, and disciplined costs offset some of the damage from exchange attrition and softer elective surgeries. For investors, the story is one of a well-capitalized operator leaning on scale, network expansion, and expense controls to navigate policy headwinds, while accepting a more modest but still steady growth path.